Rose William returned 599,583 shares to the company (SEC Form 4)

9/26/23 4:30:35 PM ET

$RETA

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $RETA alert in real time by email

SEC FORM 4 SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROSE WILLIAM

(Last)

(First)

(Middle)

4215 WEST LOVERS LANE, SUITE 200

(Street)

DALLAS

75209

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
REATA PHARMACEUTICALS INC [ RETA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/26/2023

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A common stock	09/26/2023		D		379,281	D	⁽¹⁾⁽²⁾	0	I	By trust⁽³⁾
Class A common stock	09/26/2023		D		11,618	D	⁽¹⁾⁽²⁾	0	D⁽⁴⁾
Class A common stock	09/26/2023		D		19,795	D	⁽¹⁾⁽²⁾	0	D⁽⁵⁾
Class A common stock	09/26/2023		D		7,886	D	⁽¹⁾⁽²⁾	0	I	See Footnote⁽⁶⁾
Class A common stock	09/26/2023		D		20	D	⁽¹⁾⁽²⁾	0	I	By trust⁽⁷⁾
Class A common stock	09/26/2023		D		45	D	⁽¹⁾⁽²⁾	0	I	By trust⁽⁸⁾
Class A common stock	09/26/2023		D		29	D	⁽¹⁾⁽²⁾	0	I	See Footnote⁽⁹⁾
Class A common stock	09/26/2023		D		180,909	D	⁽¹⁾⁽²⁾	0	I	See Footnote⁽¹⁰⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Class B Common Stock	⁽¹²⁾	09/26/2023		D			129,308	⁽¹²⁾	⁽¹²⁾	Class A common stock	129,308	⁽¹⁾⁽²⁾	0	D⁽⁴⁾
Class B Common Stock	⁽¹²⁾	09/26/2023		D			1,732,998	⁽¹²⁾	⁽¹²⁾	Class A common stock	1,732,998	⁽¹⁾⁽²⁾	0	I	See Footnote⁽³⁾
Class B Common Stock	⁽¹²⁾	09/26/2023		D			87,776	⁽¹²⁾	⁽¹²⁾	Class A common stock	87,776	⁽¹⁾⁽²⁾	0	I	See Footnote⁽⁶⁾
Class B Common Stock	⁽¹²⁾	09/26/2023		D			29,215	⁽¹²⁾	⁽¹²⁾	Class A common stock	29,215	⁽¹⁾⁽²⁾	0	I	See Footnote⁽⁷⁾
Class B Common Stock	⁽¹²⁾	09/26/2023		D			29,492	⁽¹²⁾	⁽¹²⁾	Class A common stock	29,492	⁽¹⁾⁽²⁾	0	I	See Footnote⁽⁸⁾
Class B Common Stock	⁽¹²⁾	09/26/2023		D			313	⁽¹²⁾	⁽¹²⁾	Class A common stock	313	⁽¹⁾⁽²⁾	0	I	See Footnote⁽⁹⁾
Class B Common Stock	⁽¹²⁾	09/26/2023		D			29,000	⁽¹²⁾	⁽¹²⁾	Class A common stock	29,000	⁽¹⁾⁽²⁾	0	I	See Footnote⁽¹¹⁾
Stock Option (right to buy)	$130.92	09/26/2023		D			6,300	⁽¹⁾⁽²⁾	06/10/2030	Class A common stock	6,300	⁽¹⁾⁽²⁾	0	D
Stock Option (right to buy)	$130.92	09/26/2023		D			760	⁽¹⁾⁽²⁾	06/10/2030	Class A common stock	760	⁽¹⁾⁽²⁾	0	D
Stock Option (right to buy)	$146.01	09/26/2023		D			5,000	⁽¹⁾⁽²⁾	06/10/2031	Class A common stock	5,000	⁽¹⁾⁽²⁾	0	D
Stock Option (right to buy)	$146.01	09/26/2023		D			810	⁽¹⁾⁽²⁾	06/10/2031	Class A common stock	810	⁽¹⁾⁽²⁾	0	D
Stock Option (right to buy)	$34.76	09/26/2023		D			11,240	⁽¹⁾⁽²⁾	06/08/2032	Class A common stock	11,240	⁽¹⁾⁽²⁾	0	D
Stock Option (right to buy)	$34.76	09/26/2023		D			3,330	⁽¹⁾⁽²⁾	06/08/2032	Class A common stock	3,330	⁽¹⁾⁽²⁾	0	D
Stock Option (right to buy)	$93.61	09/26/2023		D			4,275	⁽¹⁾⁽²⁾	06/07/2033	Class A common stock	4,275	⁽¹⁾⁽²⁾	0	D
Stock Option (right to buy)	$93.61	09/26/2023		D			1,085	⁽¹⁾⁽²⁾	06/07/2033	Class A common stock	1,085	⁽¹⁾⁽²⁾	0	D
Stock Option (right to buy)	$22.57	09/26/2023		D			6,000	⁽¹⁾⁽²⁾	12/07/2026	Class B common stock	6,000	⁽¹⁾⁽²⁾	0	D
Stock Option (right to buy)	$22.57	09/26/2023		D			1,758	⁽¹⁾⁽²⁾	12/07/2026	Class B common stock	1,758	⁽¹⁾⁽²⁾	0	D
Stock Option (right to buy)	$25.52	09/26/2023		D			6,000	⁽¹⁾⁽²⁾	06/14/2027	Class B common stock	6,000	⁽¹⁾⁽²⁾	0	D
Stock Option (right to buy)	$25.52	09/26/2023		D			2,928	⁽¹⁾⁽²⁾	06/14/2027	Class B common stock	2,928	⁽¹⁾⁽²⁾	0	D
Stock Option (right to buy)	$39.48	09/26/2023		D			8,000	⁽¹⁾⁽²⁾	06/13/2028	Class B common stock	8,000	⁽¹⁾⁽²⁾	0	D
Stock Option (right to buy)	$39.48	09/26/2023		D			1,958	⁽¹⁾⁽²⁾	06/13/2028	Class B common stock	1,958	⁽¹⁾⁽²⁾	0	D
Stock Option (right to buy)	$88.75	09/26/2023		D			9,000	⁽¹⁾⁽²⁾	06/12/2029	Class B common stock	9,000	⁽¹⁾⁽²⁾	0	D
Stock Option (right to buy)	$88.75	09/26/2023		D			978	⁽¹⁾⁽²⁾	06/12/2029	Class B common stock	978	⁽¹⁾⁽²⁾	0	D

Explanation of Responses:

1. Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2)

2. (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration.

3. These shares were owned directly by the Evelyn Potter Rose Survivor's Trust, for which Charles E. Gale and Evelyn P. Rose serve as co-trustees.

4. These shares were owned directly by William E. Rose, a director of the Issuer.

5. These shares were owned directly by Charles E. Gale.

6. These shares were owned directly by Evelyn P. Rose Fidelity SEP IRA and indirectly by Evelyn R. Rose.

7. These shares were owned indirectly by William E. Rose, a director of the Issuer, as co-trustee of the Charles Henry Rose 2001 Trust.

8. These shares were owned indirectly by William E. Rose, a director of the Issuer, as co-trustee of the John William Rose 2002 Trust.

9. These shares were owned directly by the Charles E. Gale Fidelity Rollover IRA and indirectly by Charles E. Gale.

10. These shares were owned directly by Montrose Investments I, L.P. ("Montrose"), and indirectly by William E. Rose, a director of the Issuer, as sole shareholder and sole manager of the general partner of Montrose.

11. These shares were owned indirectly by William E. Rose, a director of the Issuer, as co-trustee of the Edward Alexander Rose 1999 Trust.

12. The Class B common stock was convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock had no expiration date.

Remarks:

	/s/ Charles E. Gale, Attorney-In-Fact for William E. Rose	09/26/2023
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Get the next $RETA alert in real time by email

Date	Price Target	Rating	Analyst
7/6/2023	$140.00	Outperform	TD Cowen
6/12/2023	$80.00 → $115.00	Market Perform → Outperform	SVB Securities
10/19/2022	$75.00	Buy	Guggenheim
3/24/2022	$91.00	Buy	Goldman
3/1/2022	$39.00 → $34.00	Neutral	Goldman Sachs
12/9/2021	$39.00	Buy → Neutral	Goldman Sachs
12/9/2021	$110.00 → $37.00	Outperform → Neutral	Robert W. Baird
12/9/2021	$112.00 → $68.00	Overweight	Cantor Fitzgerald

Rose William returned 599,583 shares to the company (SEC Form 4)

Chat with this insight

Recent Analyst Ratings for $RETA

$RETA FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for SKYCLARYS issued to REATA PHARMACEUTICALS INC

$RETA Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Desai Antal Rohit returned 2,928,368 shares to the company (SEC Form 4)

Mcgaughy R Kent Jr returned 2,926,776 shares to the company, closing all direct ownership in the company (SEC Form 4)

Wortley Michael D returned 49,701 shares to the company, closing all direct ownership in the company (SEC Form 4)

$RETA Market Insights

Live Market Insights

$RETA Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$RETA SEC Filings

Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024

An Oversold Gold Miner With Strong Fundamentals--Its Relative Strength Index Is Below 20, And Its Piotroski F-Score Is 8

Reata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc.

TD Cowen initiated coverage on Reata Pharmaceuticals with a new price target

Reata Pharmaceuticals upgraded by SVB Securities with a new price target

Guggenheim initiated coverage on Reata Pharmaceuticals with a new price target

SEC Form 15-12G filed by Reata Pharmaceuticals Inc.

Reata Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update

SEC Form POSASR filed by Reata Pharmaceuticals Inc.

$RETA Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13D/A filed by Reata Pharmaceuticals Inc. (Amendment)

SEC Form SC 13D/A filed by Reata Pharmaceuticals Inc. (Amendment)

SEC Form SC 13D/A filed by Reata Pharmaceuticals Inc. (Amendment)

$RETA Press Releases

Fastest customizable press release news feed in the world

Biogen Completes Acquisition of Reata Pharmaceuticals

Reata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc.

Lifshitz Law PLLC Announces Investigations of EQRX, RVMD, NEWR, and RETA

$RETA Leadership Updates

Live Leadership Updates

$RETA Financials

Live finance-specific insights

Reata Pharmaceuticals Appoints Rajiv Patni, M.D., as Executive Vice President, Chief Research & Development Officer

Reata Announces the Appointment of Steven W. Ryder, M.D. to its Board of Directors

Biogen Completes Acquisition of Reata Pharmaceuticals

Biogen to Acquire Reata Pharmaceuticals

Reata Pharmaceuticals, Inc. Announces First Quarter 2023 Financial Results and Provides an Update on Operational Progress and Clinical Development Programs

Recent Analyst Ratings for
$RETA

$RETA
FDA approvals

$RETA
Insider Trading

$RETA
Market Insights

$RETA
Analyst Ratings

$RETA
SEC Filings

$RETA
Large Ownership Changes

$RETA
Press Releases

$RETA
Leadership Updates

$RETA
Financials